Literature DB >> 19847623

The invasiveness of five medulloblastoma cell lines in collagen gels.

Adrianna Ranger1, Warren McDonald, Emi Moore, Rolando Delmaestro.   

Abstract

Local recurrence continues to limit survival in medulloblastoma patients, largely related to the persistence of invasive cells at the site of tumour resection and leptomeningeal dissemination. Given the relative dearth of understanding of causative mechanisms behind the invasiveness of medulloblastomas, and a general lack of validated in vitro models with which to study them, our objectives were (1) to obtain quantitative data on the invasiveness of five distinct medulloblastoma cell lines within a 3-dimensional in vitro collagen-based model; and (2) to characterize some of the mechanisms behind invasion, specifically striving to identify proteolytic processes that occur as medulloblastoma cells disrupt and thereby invade the normal tissue surrounding them, and specific inhibitors of these proteolytic enzymes. Five different medulloblastoma cell lines (UW228-1, 2 and 3; Daoy, and Madsen) were implanted onto a 3-dimensional, type I collagen gel assay to assess tumour invasion distance and mean doubling time over 5 days. Proteolytic activity was assessed against collagen types I and IV by measuring the degradation of 3H-collagen I and IV to products soluble in 100% w/v trichloroacetic acid; and general (neutral) proteolytic activity evaluated by measuring the degradation of 3H-albumin. In other experiments, cells were pre-exposed to a variety of protease inhibitors, including inhibitors of metalloproteinases and cysteine, serine and aspartic proteases, and then plated to identify any inhibition of invasion. Inter-group differences in mean invasion distance were assessed by means of Student's t-tests for non-paired subjects, with P < 0.05 set as the threshold for statistical significance. For the inhibitor studies, an inhibition index, called the inhibitory concentration 50, IC-50, was calculated by performing a regression analysis for each inhibitor tested over a range of concentrations, for each cell line. Within hours of implantation, individual cells readily detached from the surface of the cell aggregates and invaded the collagen matrix, to distances of up to 1,200 mum and at rates of up to 300-mum per day; the UW228-1 cell line clearly was less invasive than the other four cell lines. Proteolytic activity was identified against collagen type I, but not against collagen type IV or albumin; but there was no apparent correlation between invasion distance and either cell doubling time or the amount of collagen type I proteolytic activity. Both metalloproteinase inhibitors suppressed tumour invasion, as did one of two cysteine protease inhibitors; but there was no tumour suppression with either serine or aspartic protease inhibition. MMP-1 and 2, and TIMP-1 and 2 all were detectable by Western blot analysis. Medulloblastoma cell invasiveness within the 3-dimensional model used here appears to depend upon a combination of metalloproteinase and cysteine protease activity, a finding that may suggest areas for potential future clinical investigation and therapy.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19847623     DOI: 10.1007/s11060-009-9962-9

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  64 in total

Review 1.  Mechanisms of glioma invasion: role of matrix-metalloproteinases.

Authors:  J H Uhm; N P Dooley; J G Villemure; V W Yong
Journal:  Can J Neurol Sci       Date:  1997-02       Impact factor: 2.104

Review 2.  Matrix metalloproteinases (MMPs) in health and disease: an overview.

Authors:  Charles J Malemud
Journal:  Front Biosci       Date:  2006-05-01

3.  Population-based epidemiologic data on brain tumors in German children.

Authors:  P Kaatsch; C H Rickert; J Kühl; J Schüz; J Michaelis
Journal:  Cancer       Date:  2001-12-15       Impact factor: 6.860

Review 4.  Proteolysis-driven oncogenesis.

Authors:  Vladislav S Golubkov; Alex Y Strongin
Journal:  Cell Cycle       Date:  2007-01-12       Impact factor: 4.534

5.  Medulloblastoma: a population-based study of 532 cases.

Authors:  R O Roberts; C F Lynch; M P Jones; M N Hart
Journal:  J Neuropathol Exp Neurol       Date:  1991-03       Impact factor: 3.685

Review 6.  Tumor progression and angiogenesis: cathepsin B & Co.

Authors:  D Keppler; M Sameni; K Moin; T Mikkelsen; C A Diglio; B F Sloane
Journal:  Biochem Cell Biol       Date:  1996       Impact factor: 3.626

7.  Expression of matrix metalloproteinases and their inhibitors in human brain tumors.

Authors:  R Béliveau; L Delbecchi; E Beaulieu; N Mousseau; Z Kachra; F Berthelet; R Moumdjian; R Del Maestro
Journal:  Ann N Y Acad Sci       Date:  1999       Impact factor: 5.691

Review 8.  Proteases and their inhibitors in human brain tumours: a review.

Authors:  H K Rooprai; D McCormick
Journal:  Anticancer Res       Date:  1997 Nov-Dec       Impact factor: 2.480

9.  Clusters of histologic characteristics in children with infratentorial neuroglial tumors. The Childhood Brain Tumor Consortium.

Authors:  F H Gilles; E L Sobel; A Leviton; C J Tavaré
Journal:  J Neurooncol       Date:  1998-08       Impact factor: 4.130

10.  Incidence and trends in pediatric malignancies medulloblastoma/primitive neuroectodermal tumor: a SEER update. Surveillance Epidemiology and End Results.

Authors:  Dawn Elizabeth McNeil; Timothy R Coté; Limin Clegg; Lucy Balian Rorke
Journal:  Med Pediatr Oncol       Date:  2002-09
View more
  5 in total

1.  Valproic acid treatment response in vitro is determined by TP53 status in medulloblastoma.

Authors:  Bruna Mascaro-Cordeiro; Indhira Dias Oliveira; Francine Tesser-Gamba; Lorena Favaro Pavon; Nasjla Saba-Silva; Sergio Cavalheiro; Patrícia Dastoli; Silvia Regina Caminada Toledo
Journal:  Childs Nerv Syst       Date:  2018-05-22       Impact factor: 1.475

2.  CARP-1 functional mimetics: a novel class of small molecule inhibitors of medulloblastoma cell growth.

Authors:  Abdelkader E Ashour; Shazia Jamal; Vino T Cheryan; Magesh Muthu; Khairy M A Zoheir; Ahmed M Alafeefy; Adel R Abd-Allah; Edi Levi; Adi L Tarca; Lisa A Polin; Arun K Rishi
Journal:  PLoS One       Date:  2013-06-24       Impact factor: 3.240

3.  Neural stem cell-mediated CE/CPT-11 enzyme/prodrug therapy in transgenic mouse model of intracerebellar medulloblastoma.

Authors:  M Gutova; G M Shackleford; V Khankaldyyan; K A Herrmann; X-H Shi; K Mittelholtz; Y Abramyants; M S Blanchard; S U Kim; A J Annala; J Najbauer; T W Synold; M D'Apuzzo; M E Barish; R A Moats; K S Aboody
Journal:  Gene Ther       Date:  2012-03-08       Impact factor: 5.250

4.  Integrated Proteomic and Transcriptomic-Based Approaches to Identifying Signature Biomarkers and Pathways for Elucidation of Daoy and UW228 Subtypes.

Authors:  Roger Higdon; Jessie Kala; Devan Wilkins; Julia Fangfei Yan; Manveen K Sethi; Liang Lin; Siqi Liu; Elizabeth Montague; Imre Janko; John Choiniere; Natali Kolker; William S Hancock; Eugene Kolker; Susan Fanayan
Journal:  Proteomes       Date:  2017-02-03

5.  Medullospheres from DAOY, UW228 and ONS-76 cells: increased stem cell population and proteomic modifications.

Authors:  Cristina Zanini; Elisabetta Ercole; Giorgia Mandili; Roberta Salaroli; Alice Poli; Cristiano Renna; Valentina Papa; Giovanna Cenacchi; Marco Forni
Journal:  PLoS One       Date:  2013-05-24       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.